SkinBioTherapeutics (AIM:SBTX) said that its board has completed an investigation into financial statements for the year ended 30 June 2025, and it expects to publish the HY26 results together with restated (unaudited) FY25 results shortly.
At the same time, it has now appointed Saffrey as its independent auditor with immediate effect for the financial year ending 30 June.
It noted trading in the company's shares is expected to resume following publication of the results and remediation actions.
The suspension of trading follows the delay to the planned end-of-May publication of the results whilst the investigating committee gathered information and finalised remediation plans.
